Bank of New York Mellon Corp boosted its position in BioScrip Inc. (NASDAQ:BIOS) by 10.7% during the second quarter, Holdings Channel reports. The institutional investor owned 301,166 shares of the company’s stock after buying an additional 28,993 shares during the period. Bank of New York Mellon Corp owned about 0.44% of BioScrip worth $768,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of BioScrip by 1.2% in the first quarter. Geode Capital Management LLC now owns 452,925 shares of the company’s stock worth $969,000 after buying an additional 5,437 shares in the last quarter. Keane Capital Partners LLC purchased a new position in shares of BioScrip during the first quarter worth $880,000. Finally, Prescott Group Capital Management L.L.C. increased its position in shares of BioScrip by 80.8% in the second quarter. Prescott Group Capital Management L.L.C. now owns 2,237,608 shares of the company’s stock worth $5,706,000 after buying an additional 1,000,000 shares in the last quarter. 82.89% of the stock is owned by institutional investors and hedge funds.
Shares of BioScrip Inc. (NASDAQ:BIOS) traded down 0.167% during trading on Wednesday, reaching $2.995. 573,951 shares of the company were exchanged. BioScrip Inc. has a one year low of $1.19 and a one year high of $3.43. The stock’s market capitalization is $341.07 million. The stock has a 50-day moving average price of $2.88 and a 200-day moving average price of $2.67.
BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.05. The firm had revenue of $232.50 million for the quarter, compared to the consensus estimate of $229.58 million. BioScrip’s revenue was down 11.4% on a year-over-year basis. Analysts forecast that BioScrip Inc. will post ($0.27) EPS for the current year.
Separately, Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Monday, July 11th.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip Inc. (NASDAQ:BIOS).
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.